Laboratorio Farmaceutico Erfo Balance Sheet Health
Financial Health criteria checks 5/6
Laboratorio Farmaceutico Erfo has a total shareholder equity of €7.5M and total debt of €398.0K, which brings its debt-to-equity ratio to 5.3%. Its total assets and total liabilities are €10.5M and €3.0M respectively. Laboratorio Farmaceutico Erfo's EBIT is €588.9K making its interest coverage ratio 20. It has cash and short-term investments of €1.5M.
Key information
5.3%
Debt to equity ratio
€398.02k
Debt
| Interest coverage ratio | 20x |
| Cash | €1.52m |
| Equity | €7.54m |
| Total liabilities | €2.98m |
| Total assets | €10.52m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: RK7's short term assets (€3.7M) exceed its short term liabilities (€2.0M).
Long Term Liabilities: RK7's short term assets (€3.7M) exceed its long term liabilities (€1.0M).
Debt to Equity History and Analysis
Debt Level: RK7 has more cash than its total debt.
Reducing Debt: RK7's debt to equity ratio has increased from 0% to 5.3% over the past 5 years.
Debt Coverage: RK7's debt is well covered by operating cash flow (329.4%).
Interest Coverage: RK7's interest payments on its debt are well covered by EBIT (20x coverage).